Welcome to our dedicated page for Athira Pharma SEC filings (Ticker: ATHA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Athira Pharma’s biotech disclosures can feel like studying for a PhD in neuroscience. The company’s 10-K weaves through R&D expenses, HGF-system science, and cash-runway projections, while each 8-K details pivotal trial read-outs. If you have ever asked, “How do I find Athira Pharma’s quarterly earnings report 10-Q filing?” or “Where are Athira Pharma insider trading Form 4 transactions?”, this page is designed for you.
Stock Titan’s AI instantly converts dense regulatory language into plain-English summaries. Whether it is an Athira Pharma annual report 10-K simplified for pipeline timelines, an Athira Pharma 8-K material events explained alert on a Phase 2 data release, or Athira Pharma executive stock transactions Form 4 in real-time, our platform highlights the metrics that matter—burn rate, trial milestones, and partnership revenues.
All SEC documents appear here the moment EDGAR posts them. You will find:
- 10-Q filings with AI commentary on R&D spend and cash position
- Form 4 insider buying and selling, searchable as “Athira Pharma insider trading Form 4 transactions”
- Proxy statements that clarify Athira Pharma proxy statement executive compensation
- 8-K updates on FDA feedback, study enrollment, or CEO changes
Need to compare quarter-over-quarter burn or evaluate dilution risk? Our expert analysis surfaces those figures within seconds, letting you focus on decision-making, not document hunting. Understanding Athira Pharma SEC documents with AI means no more sifting through hundreds of pages—just actionable insight tailored to neurodegeneration investors.
Athira Pharma (ATHA) filed its Q3 2025 10‑Q reporting narrower losses and a streamlined cost base. Net loss was $6.6 million for the quarter, a sharp improvement from $28.7 million a year ago, as research and development and general and administrative expenses declined. Other income contributed modestly.
Cash, cash equivalents and investments were $25.2 million as of September 30, 2025. Management states this balance is sufficient to fund operating expenses and capital needs for at least the next 12 months, and the company maintains a $75.0 million at‑the‑market equity facility with Cantor Fitzgerald and BTIG, with no sales to date.
The company effected a 1‑for‑10 reverse stock split on September 17, 2025 and subsequently regained Nasdaq minimum bid compliance on October 2, 2025. Athira has paused fosgonimeton development and is focusing on ATH‑1105 for ALS; a completed Phase 1 in healthy volunteers showed a favorable safety profile. Shares outstanding were 3,943,887 as of November 5, 2025.
Athira Pharma (ATHA)
The company notes that information under Items 2.02 and 7.01, and Exhibit 99.1, is furnished and not deemed filed under the Exchange Act. Athira also highlights its disclosure channels, including its website, investor site, and social media accounts on X (@athirapharma), LinkedIn, Instagram (@athirapharma), and Facebook.
A Schedule 13G/A reports that Steven Michael Oliveira and affiliated entities collectively disclose 161,218 shares of Athira Pharma common stock, representing
FAQ
What is the current stock price of Athira Pharma (ATHA)?
What is the market cap of Athira Pharma (ATHA)?
